Literature DB >> 16837722

Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates.

Maud Henry1, Ibrahima Diallo, Julien Bordes, Sidy Ka, Bruno Pradines, Bakary Diatta, Papa Sialou M'Baye, Mouhamadou Sane, Massamba Thiam, Pape Mandoumbe Gueye, Boubacar Wade, Jean Etienne Touze, Jean-Marc Debonne, Christophe Rogier, Thierry Fusai.   

Abstract

The chemosusceptibility and genetic polymorphism of Plasmodium falciparum populations from 48 patients hospitalized for malaria at the Hospital Principal in Dakar, Senegal were investigated during the 2002 malaria transmission season. Sixty-two percent of the isolates collected were from patients with severe malaria and 38% were from patients with mild malaria. In vitro activities of chloroquine, quinine, cycloguanil, atovaquone, mefloquine, halofantrine, and artesunate were evaluated. The prevalence of mutations in the Plasmodium falciparum dihydrofolate reductase (dhfr) and dihyropteroate synthetase (dhps) genes and the P. falciparum chloroquine resistance transporter (Pfcrt) gene associated with cycloguanil, pyrimethamine, sulfadoxine, and chloroquine resistance were estimated. The genetic polymorphism of the parasite populations was evaluated by analysis of the highly polymorphic regions of merozoite surface protein 1 (msp1) block 2 and msp2. Seventy percent of the isolates were assessed by an in vitro assay. Fifty-two percent of the isolates were chloroquine resistant, 45% were cycloguanil resistant, and 24% were atovaquone resistant. Four percent had low susceptibility to quinine. The Pfcrt and dhfr mutations were associated with in vitro chloroquine- and antimetabolic drug-resistant isolates, respectively. Approximately 70% of the isolates contained two or more clones. Genetic diversity of P. falciparum was high. The prevalence of allelic family K1 of msp1 was 68%. Isolates of P. falciparum were highly resistant to chloroquine, cycloguanil and atovaquone. The transmission rate of malaria in Dakar is low but a high degree of genetic polymorphism can increase severe malaria, as shown by persons coming to Dakar from areas highly endemic for malaria. Areas with urban malaria should use vector control measures and efficient chemoprophylaxis for non-immune populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837722

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  59 in total

1.  Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda.

Authors:  Frederick N Baliraine; Samuel L Nsobya; Jane Achan; James K Tibenderana; Ambrose O Talisuna; Bryan Greenhouse; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.

Authors:  Helene Savini; Hervé Bogreau; Lionel Bertaux; Housem Bouchiba; Philippe Kraemer; Daniel Parzy; Eric Garnotel; Christophe Rogier; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

3.  Molecular Markers and In Vitro Susceptibility to Doxycycline in Plasmodium falciparum Isolates from Thailand.

Authors:  Tiphaine Gaillard; Kanlaya Sriprawat; Sébastien Briolant; Chirapat Wangsing; Nathalie Wurtz; Meïli Baragatti; Morgane Lavina; Aurélie Pascual; François Nosten; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.

Authors:  Aurélie Pascual; Maud Henry; Sébastien Briolant; Serge Charras; Eric Baret; Rémy Amalvict; Emilie Huyghues des Etages; Michel Feraud; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

5.  Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.

Authors:  Sébastien Briolant; Maud Henry; Claude Oeuvray; Rémy Amalvict; Eric Baret; Eric Didillon; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cells.

Authors:  Dhaniah Mohamad; Rapeah Suppian; Norazmi Mohd Nor
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Parasite polymorphism and severe malaria in Dakar (Senegal): a West African urban area.

Authors:  Ndeye Sakha Bob; Bernard Marcel Diop; Francois Renaud; Laurence Marrama; Patrick Durand; Adama Tall; Boubacar Ka; Marie Therese Ekala; Christiane Bouchier; Odile Mercereau-Puijalon; Ronan Jambou
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

8.  Determinants of compliance with malaria chemoprophylaxis among French soldiers during missions in inter-tropical Africa.

Authors:  Noémie Resseguier; Vanessa Machault; Lénaick Ollivier; Eve Orlandi-Pradines; Gaetan Texier; Bruno Pradines; Jean Gaudart; Alain Buguet; Catherine Tourette-Turgis; Christophe Rogier
Journal:  Malar J       Date:  2010-02-03       Impact factor: 2.979

9.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

10.  Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial.

Authors:  Jane Achan; James K Tibenderana; Daniel Kyabayinze; Fred Wabwire Mangen; Moses R Kamya; Grant Dorsey; Umberto D'Alessandro; Philip J Rosenthal; Ambrose O Talisuna
Journal:  BMJ       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.